Type of Cancer
Lung
Phase
Division (Location)
Study ID
NCT#
Brief Description
Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.